New pill takes on hard-to-treat tumors in early trial
NCT ID NCT07213609
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 24 times
Summary
This study tests an experimental oral drug (GSK5460025) in adults with advanced solid tumors that have specific genetic features (dMMR or MSI-H), which often make them harder to treat. The trial has two parts: first, finding a safe dose and checking for side effects; second, seeing if the drug alone or with other cancer treatments can shrink tumors. About 47 participants will take part, and the goal is to learn if the drug is safe and effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
GSK Investigational Site
RECRUITINGCanton, Ohio, 44718, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGHamilton, Ontario, L8V 5C2, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGToronto, Ontario, M5G 2M9, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGMontreal, Quebec, H4A 3J1, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
GSK Investigational Site
RECRUITINGChiba, 277-8577, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGOsaka, 573-1191, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGTokyo, 104-0045, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
GSK Investigational Site
RECRUITINGTokyo, 135-8550, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.